Aquinox Pharmaceuticals Inc. and Neoleukin Therapeutics, Inc. have entered into a definitive merger agreement under which Aquinox will acquire Neoleukin, which is expected to close on or about August 8th, 2019. Aquinox will acquire all of the outstanding capital stock of Neoleukin in exchange for a combination of common and preferred shares. In connection with the merger, Aquinox will be renamed as Neoleukin Therapeutics, Inc.   The combined company will focus on the development and commercial...